800-845-6913
Tuteur & Associates, LLC | Knowledge is Power.
February 15, 2008
BIRMINGHAM, Ala.—(BUSINESS WIRE)— Lawsuits have been filed against Bayer AG (NYSE:BAY) on behalf of plaintiffs throughout the United States, who allegedly suffered permanent kidney damage after being given Trasylol®—a Bayer-manufactured drug used to prevent excessive bleeding during coronary artery bypass graft surgery (also called CABG or more commonly bypass). According to CBS News, 60 Minutes will report Sunday night that 22,000 additional lives could have been saved had the FDA taken action to remove Trasylol from the market in 2006. Dr. Dennis Mangano, a leading researcher in the field, whose January 2006 New England Journal of Medicine article set out the dangers of Trasylol (also known as aprotinin), reports that Bayer AG had done internal studies that were not presented to the FDA at a September 2006 advisory panel meeting that would have confirmed the dangers of this drug. FDA eventually requested marketing suspension of Trasylol, which finally occurred in November of 2007. The market suspension is now worldwide.
According to German scientist, Dr. Juergen Fischer, who was interviewed for the 60 Minutes segment, Bayer AG has known since the 1980s that Trasylol caused severe kidney damage, but undertook no study during the drug’s development to look at these side effects.
Continue reading, ‘60 Minutes to Air Report on Dangers of Trasyol.’